May 29, 2020 10:12 AM EDTUpdated 10:36 AM
News Briefing

Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

ENDPOINTS

→ Months af­ter a de­press­ing end to Min­er­va Neu­ro­sciences‘ quest to de­vel­op a de­pres­sion drug, the Waltham, Mass­a­chu­setts-based drug de­vel­op­er un­veiled more bad news …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times